Ardaman Shergill, MD - UChicago Medicine

Dr. Ardaman Shergill, MD

Claim this profile

University of Chicago Comprehensive Cancer Center

Studies Cervical Adenocarcinoma
Studies Colorectal Cancer
25 reported clinical trials
63 drugs studied

Area of expertise

1Cervical Adenocarcinoma
Ardaman Shergill, MD has run 10 trials for Cervical Adenocarcinoma. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive
2Colorectal Cancer
Ardaman Shergill, MD has run 10 trials for Colorectal Cancer. Some of their research focus areas include:
Stage IV
Stage III
BRAF negative

Affiliated Hospitals

Image of trial facility.
University Of Chicago Comprehensive Cancer Center
Image of trial facility.
UC Comprehensive Cancer Center At Silver Cross

Clinical Trials Ardaman Shergill, MD is currently running

Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Atezolizumab + Chemotherapy

for Neuroendocrine Carcinoma

This trial is testing a new treatment combining an immune-boosting drug with standard chemotherapy for patients with a specific type of aggressive cancer that has spread. The goal is to help the immune system fight the cancer and use chemotherapy to kill cancer cells.
Recruiting1 award Phase 2 & 310 criteria

More about Ardaman Shergill, MD

Clinical Trial Related2 years of experience running clinical trials · Led 25 trials as a Principal Investigator · 12 Active Clinical Trials
Treatments Ardaman Shergill, MD has experience with
  • Cisplatin
  • Irinotecan
  • Fluorouracil
  • Cetuximab
  • Atezolizumab
  • Oxaliplatin
Breakdown of trials Ardaman Shergill, MD has run
Cervical Adenocarcinoma
Colorectal Cancer
Cancer
Parotid Gland Cancer
Colon Cancer

Other Doctors you might be interested in

Shaker Dakhil, M.D.Ascension Via Christi Hospitals Wichita
Khalid MatinPeninsula Cancer Institute-Newport News
Isao SuzakiGSK Investigational Site

Frequently asked questions

Do I need insurance to participate in a trial?
What does Ardaman Shergill, MD specialize in?
Is Ardaman Shergill, MD currently recruiting for clinical trials?
Are there any treatments that Ardaman Shergill, MD has studied deeply?
What is the best way to schedule an appointment with Ardaman Shergill, MD?
What is the office address of Ardaman Shergill, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security